GLAUKOS CORP.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 907
- Market Cap
- $7.4B
- Website
- http://www.glaukos.com
Clinical Trials
63
Trial Phases
5 Phases
Drug Approvals
2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (57 trials with phase data)• Click on a phase to view related trials
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- Conditions
- Glaucoma
- Interventions
- Drug: Gen 2 Travoprost Intracameral ImplantOther: Placebo eye dropsProcedure: Sham Procedure
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 610
- Registration Number
- NCT07075718
- Locations
- 🇺🇸
Glaukos Investigative Site, Oklahoma City, Oklahoma, United States
🇺🇸Glaukos Clinical Site, El Paso, Texas, United States
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
- Conditions
- Glaucoma, Open-angleOcular Hypertension (OHT)Phacoemulsification Cataract Surgery
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT06848946
- Locations
- 🇺🇸
Glaukos Investigator Site, Kenosha, Wisconsin, United States
Performance of the Travoprost Intraocular Implant
- Conditions
- Glaucoma, Open-AngleOcular Hypertension
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 210
- Registration Number
- NCT06582732
- Locations
- 🇦🇲
Glaukos Clinical Study Site, Yerevan, Armenia
Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension
- Conditions
- Ocular HypertensionOpen Angle Glaucoma
- Interventions
- First Posted Date
- 2023-12-01
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06152861
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Newport Beach, California, United States
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
- Conditions
- Glaucoma, Open-Angle
- Interventions
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Glaukos Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT06066645
- Locations
- 🇺🇸
Glaukos Clinical Study Site, Colorado Springs, Colorado, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Controlled Release Drug Delivery Market Expands with Major Pharma Investment in Precision Medicine Technologies
Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.
iVeena Submits IND Application for Novel Non-Atropine Eye Drop to Treat Pediatric Myopia
iVeena Delivery Systems has submitted an Investigational New Drug application to the FDA for IVMED-85, a first-in-class eye drop targeting pediatric myopia through lysyl oxidase activation.
Pipeline Analysis Reveals 20+ Therapies in Development for Open-Angle Glaucoma Treatment
DelveInsight's latest report identifies 18+ companies developing 20+ therapeutic candidates for open-angle glaucoma, with several treatments advancing through late-stage clinical trials.